News Results
There are 688,666 News Results
Jun 2, 2017
WOODCLIFF LAKE, N.J., June 3, 2017 /PRNewswire/ -- Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as...
Jun 6, 2017
ATLANTA, June 7, 2017 /PRNewswire/ -- All 20 of the most popular investment products viewed in May by institutional investment professionals using eVestment were equity focused in May 2017, according...
Jul 6, 2017
NEW YORK, July 7, 2017 /PRNewswire/ -- OB Realty, LLC, an affiliate of Opus Bank, the former secured lender to BeamReach Solar, is pleased to announce that since April, it...
Jul 9, 2017
NEW YORK, July 10, 2017 /PRNewswire/ --
Jul 9, 2017
NEW YORK, July 10, 2017 /PRNewswire/ --
Jul 24, 2017
WOODCLIFF LAKE, N.J., July 25, 2017 /PRNewswire/ -- Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the...
Sep 9, 2017
WOODCLIFF LAKE, N.J., Sept. 10, 2017 /PRNewswire/ -- Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating...
Sep 25, 2017
WOODCLIFF LAKE, N.J., Sept. 26, 2017 /PRNewswire/ -- Eisai Inc. today announced the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for lenvatinib...
Oct 15, 2017
WASHINGTON, Oct. 16, 2017 /PRNewswire-USNewswire/ -- Technology is advancing at lightning speed. Innovations like smart cities, cars and appliances and connected health care devices are quickly becoming part of our...
Dec 9, 2017
Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies
ATLANTA, Dec. 10, 2017 /PRNewswire-USNewswire/ -- Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in...
